Literature DB >> 26663435

Subtype prediction in primary aldosteronism: measurement of circadian variation of adrenocortical hormones and 24-h urinary aldosterone.

Hiroki Kobayashi1, Akira Haketa1, Takahiro Ueno1, Ryo Suzuki1, Noriko Aoi2, Yukihiro Ikeda1, Kazunobu Tahira1, Yoshinari Hatanaka1, Sho Tanaka1, Hiromasa Otsuka3, Masanori Abe1, Noboru Fukuda1,4, Masayoshi Soma1,3.   

Abstract

OBJECTIVE: Currently, adrenal venous sampling (AVS) is the only reliable method to distinguish unilateral from bilateral hyperaldosteronism in primary aldosteronism (PA). However, AVS is costly and time-consuming compared with simple blood tests. In this study, we conducted a retrospective study to determine whether circadian variation in plasma adrenocortical hormone levels (i.e. aldosterone, cortisol and ACTH) and a 24-h urinary aldosterone could contribute to the clinical differentiation between unilateral hyperaldosteronism (UHA) and bilateral hyperaldosteronism (BHA).
DESIGN: In 64 patients who were diagnosed with PA and underwent AVS, 32 and 22 patients were diagnosed with UHA and BHA, respectively. Plasma adrenocortical hormone levels at 0:00, 6:00, 12:00 and 18:00 and 24-h urinary aldosterone under a condition of 6 g daily dietary sodium chloride intake were measured.
RESULTS: Baseline plasma aldosterone concentration (PAC) and 24-h urinary aldosterone level in patients with UHA were significantly higher than in patients with BHA, particularly at 6:00. The area under the ROC curve for PAC at 0:00, 6:00, 12:00 and 18:00 and 24-h urinary aldosterone to discriminate UHA and BHA was 0·839 [95% confidence interval (CI); 0·73-0·95], 0·922 (95% CI; 0·85-1·00), 0·875 (95% CI; 0·78-0·97), 0·811 (95% CI; 0·69-0·93), 0·898 (95% CI; 0·81-0·99), respectively.
CONCLUSIONS: PAC at different blood sampling times and 24-h urinary aldosterone level may be diagnostically helpful in discriminating between UHA and BHA. We believe that these tests could reduce the number of unnecessary AVS procedures.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26663435     DOI: 10.1111/cen.12998

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  Reassessment of Urinary Aldosterone Measurement After Saline Infusion in Primary Aldosteronism.

Authors:  Hiroki Kaneko; Hironobu Umakoshi; Yuki Ishihara; Kazutaka Nanba; Mika Tsuiki; Toru Kusakabe; Noriko Satoh-Asahara; Akihiro Yasoda; Tetsuya Tagami
Journal:  J Endocr Soc       Date:  2020-07-22

2.  Identifying unilateral disease in Chinese patients with primary aldosteronism by using a modified prediction score.

Authors:  Ying Zhang; Wenquan Niu; Fangfang Zheng; Hua Zhang; Wenlong Zhou; Zhoujun Shen; Jianzhong Xu; Xiaofeng Tang; Jin Zhang; Ping-Jin Gao; Ji-Guang Wang; Limin Zhu
Journal:  J Hypertens       Date:  2017-12       Impact factor: 4.844

3.  Plasma adrenocorticotropic hormone but not aldosterone is correlated with blood pressure in patients with aldosterone-producing adenomas.

Authors:  Hiroki Kobayashi; Akira Haketa; Ueno Takahiro; Hiromasa Otsuka; Sho Tanaka; Yoshinari Hatanaka; Yukihiro Ikeda; Masanori Abe; Noboru Fukuda; Masayoshi Soma
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-12-05       Impact factor: 3.738

4.  ACTH Stimulation Maximizes the Accuracy of Peripheral Steroid Profiling in Primary Aldosteronism Subtyping.

Authors:  Yuta Tezuka; Kae Ishii; Lili Zhao; Yuto Yamazaki; Ryo Morimoto; Hironobu Sasano; Aaron M Udager; Fumitoshi Satoh; Adina F Turcu
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 6.134

Review 5.  New advances in the diagnosis of primary aldosteronism.

Authors:  Hang Shen; Zhi-Xin Xu; Qi-Fu Li
Journal:  Chronic Dis Transl Med       Date:  2020-02-14

6.  The Instigation of the Associations Between Melatonin, Circadian Genes, and Epileptic Spasms in Infant Rats.

Authors:  Lin Wan; Xiu-Yu Shi; Wen-Rong Ge; Yu-Lin Sun; Shan Zhang; Jing Wang; Lin-Yan Hu; Li-Ping Zou; Guang Yang
Journal:  Front Neurol       Date:  2020-10-26       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.